轻链多发性髓瘤的临床特征,治疗反应和结果
Abiola Bolarinwa1, Saurabh Zanwar1, Nadine Abdallah1
1Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
American journal of hematology
|October 4, 2025
概括
轻链多发性髓瘤 (LCMM) 具有独特的临床和细胞遗传特征,包括较高的功能衰竭率和特定的遗传标记. 尽管存在这些差异,但LCMM患者的生存结果与非LCMM患者相似.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 轻链多发性骨髓瘤 (LCMM) 是一种多发性骨髓瘤 (MM) 的亚型,其特点是仅产生免疫球蛋白轻链,占MM新病例的15%-20%.
- 在生产完整免疫球蛋白 (非LCMM) 的LCMM和MM之间存在有限的综合比较.
研究的目的:
- 描述LCMM的独特临床和细胞遗传特征.
- 评估与非LCMM对照组相比,LCMM患者的长期结果.
主要方法:
- 在2004年至2022年期间诊断出852名LCMM患者的回顾性研究.
- 与年龄,性别和诊断年相匹配的非LCMM对照进行比较.
- 临床和细胞遗传特征以及生存结果的单变量和多变量分析.
主要成果:
- 较频出现的LCMM患者具有较高的肌素,β-2-微球蛋白,LDH,高血,t(11;14) 和del(13q).
- 较少的LCMM患者患有IMS-IMWG高风险疾病,超化,t(4;14) 和低血清白蛋白.
- 较高的肌素,t(11;14),和del(13q) 独立地与LCMM相关;IMS-IMWG高风险疾病和超双质体的频率较低.
结论:
- 慢性瘤表现出明显的临床和细胞遗传特征,包括较高的功能衰竭率,t(11;14),和del(13q).
- 在LCMM中,IMS-IMWG高风险疾病和超积症的发病率较低.
- 尽管特征有差异,但在LCMM和非LCMM患者中,无进展和整体存活率是可比的.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
9.1K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
7.2K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
